Apollomics Inc. Class A (APLM)
NASDAQ: APLMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
APLM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $45.28M
- EPS (TTM)
- -$0.25
- Dividend yield
- None
- 52-week range
- 12.58 – 28.29
- Day range
- 15.54 – 16.51
- Volume / Avg
- 4.07K / 11.07K
- Beta
- —
- Shares outstanding
- 2.91M
52-week range
APLM stock today
On Nov 20, APLM ended the session at $15.54, shedding $1.16 (6.92%), versus the S&P 500's 3.70% decline. Trading was light, with 4.07K shares changing hands, about 37% of the average daily volume. At this level, APLM sits near the bottom of its 52-week range of $12.58 to $28.29: 45.1% below the high, set on Sep 3, 2026 and 23.5% above the low.
APLM is down 16.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 7.4%. Apollomics has posted a net loss over the last twelve months (EPS of -$0.25), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Apollomics
Company profileApollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Hung-Wen Chen
- Headquarters
- Foster City, CA
- Employees
- 14
- Website
- apollomicsinc.com
Financial highlights
Full financialsIn fiscal 2024, Apollomics generated $0 in revenue, up 0.0% from fiscal 2023. Apollomics reported a net loss of $53.9 million, compared with a loss of $172.6 million a year earlier. Diluted earnings per share came in at -$52.80.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-53.86M | $-172.60M | $-240.81M | $-94.80M | $-74.82M |
| EPS (diluted) | $-52.80 | $-231.99 | $-844.95 | $-3.37 | $-0.21 |
Apollomics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs APLM |
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs APLM |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs APLM |
| GANXGain Therapeutics Inc. | 0.9994 | -4.82% | $44.50M | vs APLM |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs APLM |
| TNXPTonix Pharmaceuticals Holding Corp. | 2.38 | -6.67% | $46.25M | vs APLM |
| ANVSAnnovis Bio Inc. | 0.7113 | -4.96% | $44.12M | vs APLM |
| VRCAVerrica Pharmaceuticals Inc. | 2.74 | -5.03% | $47.07M | vs APLM |
Indexes, lists and sector
Apollomics stock FAQ
What is Apollomics's stock price today?
APLM last traded at $15.54 as of Nov 20, 4:00 PM EST, down 6.92% on the day. Prices are delayed at least 15 minutes.
Does Apollomics pay a dividend?
No. Apollomics does not currently pay a regular cash dividend.
Who is Apollomics's CEO?
Mr. Hung-Wen Chen is the chief executive officer of Apollomics Inc. Class A, which has about 14 employees.
Has APLM ever split its stock?
Yes. The most recent APLM stock split was a 1-for-100 split on Nov 25, 2024.
What is the APLM 52-week high?
The 52-week high for APLM is $28.29 and the 52-week low is $12.58. The stock is currently 45.1% below its high.